NCT03958383 2025-04-18
IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma
University of Wisconsin, Madison
Phase 1/2 Active not recruiting
Clinical Trials
7 trialsNCT03209869 2022-09-13
Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2
University of Wisconsin, Madison
Phase 1 Withdrawn
NCT00590824 2019-11-21
Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma
University of Wisconsin, Madison
Phase 2 Completed
NCT00109863 2019-11-19
Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma
University of Wisconsin, Madison
Phase 2 Completed
NCT01334515 2019-10-21
Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma
Children's Oncology Group
Phase 2 Completed
NCT00082758 2015-02-12
hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma
Children's Oncology Group
Phase 2 Completed
NCT00003750 2014-08-08
Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors
Children's Oncology Group
Phase 1 Completed